Chantix

Chantix (varenicline) is a prescription medication used to treat smoking addiction

Chantix is a prescription medication used to treat smoking addiction. Chantix was approved in May of 2006 in the U.S. as an aid to . It has been prescribed to more than 4 million patients in the United States since its approval. is the first non-nicotine prescription treatment for in almost a decade.

, is a selective nicotinic acetylcholine receptor partial agonist. As a partial agonist, it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products, and through these mechanisms, it can assist some patients in stopping smoking.

Do you have a claim?

If your loved one has suffered a serious injury or death as a result of a side effect of , you may be entitled to compensation for medical expenses, loss of wages, and pain and suffering.

Please contact our Chantix lawyers today by filling out the brief questionnaire, or by calling our toll free number (1-800-898-2034) for a free, no-cost, no-obligation legal evaluation of your case.

Latest News

FDA expands Chantix warnings to include increased heart risks

fda logo 100x100The black-box warning on Pfizer’s smoking-cessation drug Chantix (varenicline) just got bigger, following the results of a new study that found the drug caused an increased risk of heart attack and other adverse cardiac events in some patients. According to the U.S. Food and Drug Administration, the warning on Chantix labeling will include information about the safety and effectiveness of the drug in patients with existing cardiovascular disease and those with chronic obstructive pulmonary disease (COPD).

Read the rest of this entry »

Chantix significantly increases cardiovascular risks, according to another new study

Last month, the Food and Drug Administration warned of newly discovered cardiovascular risks associated with Pfizer’s popular smoking-cessation drug Chantix. But it turns out those risks, which include higher occurrence of heart attack and other adverse cardiovascular events in Chantix users with heart disease, pale in comparison to the findings of a larger study that found many of the same risks exist in Chantix patients with no heart disease.

Read the rest of this entry »

FDA warns of new heart risks associated with Chantix

For many smokers trying to kick their addiction, the latest news about the dangers of Pfizer’s smoking-cessation drug Chantix presents as a damned if you do, damned if you don’t dilemma. The U.S. Food and Drug Administration issued an alert yesterday, warning that use of the popular drug could lead to increased risk of heart attack and other adverse cardiovascular events.

Read the rest of this entry »